Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

ALLERGAN PLC (AGN)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
11/17/2017 11/20/2017 11/21/2017 11/22/2017 11/24/2017 Date
174.88(c) 171.12(c) 170.67(c) 174.83(c) 174.99 Last
2 819 304 3 003 555 2 957 591 2 856 367 116 179 Volume
+0.04% -2.15% -0.26% +2.44% +0.09% Change
More quotes
Financials ($)
Sales 2017 15 885 M
EBIT 2017 7 662 M
Net income 2017 -5 870 M
Debt 2017 24 767 M
Yield 2017 1,64%
Sales 2018 15 726 M
EBIT 2018 7 325 M
Net income 2018 -51,1 M
Debt 2018 22 939 M
Yield 2018 1,66%
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 5,22x
EV / Sales2018 5,16x
Capitalization 58 146 M
More Financials
Company
Allergan Plc engages in the research, development, and manufacture of pharmaceutical products.It operates through the following segments: US Specialized Therapeutics; US General Medicine, and International.The US Specialized Therapeutics segment includes sales and expenses relating to branded... 
Sector
Pharmaceuticals
Calendar
11/30 | 05:45pmPresentation
More about the company
Surperformance© ratings of Allergan plc
Trading Rating : Investor Rating :
More Ratings
Latest news on ALLERGAN PLC
11:38a ALLERGAN : to Present at the 2017 Citi Global Healthcare Conference
11/22 ALLERGAN : to Present at the 2017 Citi Global Healthcare Conference
11/21 ALLERGAN : to Present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conf..
11/21 ALLERGAN : Receives FDA Approval For Use of VRAYLAR cariprazine in the Maintenan..
11/17 ALLERGAN PLC : . (AGN) Shares Bought by Bank Hapoalim BM
11/16 ALLERGAN : to Present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conf..
11/16 ALLERGAN : Overactive Bladder Causes Significant Burden Regardless of Age Amongs..
11/16 ALLERGAN PLC : ex-dividend day
11/15 ALLERGAN : Receives FDA Approval for Use of VRAYLAR in the Maintenance Treatment..
11/14 ALLERGAN : Overactive Bladder Causes Significant Burden, Regardless of Age Among..
More news
Sector news : Pharmaceuticals - NEC
09:31aDJBAYER : Amikacin Inhale Fails to Meet Objectives in Phase 3 Trial
11/23 German chemicals companies should review British ops - trade body
11/23DJGLAXOSMITHKLINE : Files Additional Trelegy Ellipta Application to FDA
11/22 BAYER : Brazil pushes back decision on Bayer-Monsanto tie-up
11/22 European shares retreat on euro bounce; UK flat after budget
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
11/22 Restasis Buyers Hit Allergan With An Anti-Trust Lawsuit
11/22 Tracking Wallace Weitz's Weitz Investment Management Portfolio - Q3 2017 Upda..
11/21 TEVA PHARMACEUTICAL : Generidiculous!
11/20 Tracking The Parnassus Core Equity Fund - Q3 2017 Update
11/20 Cost of U.S. opioid epidemic tops $500B
Chart ALLERGAN PLC
Duration : Period :
Allergan plc Technical Analysis Chart | AGN | IE00BY9D5467 | 4-Traders
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 228 $
Spread / Average Target 31%
EPS Revisions
Managers
NameTitle
Brenton L. Saunders Chairman, President & Chief Executive Officer
Robert A. Stewart Chief Operating Officer
Maria Teresa Hilado Chief Financial Officer
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC-16.75%58 146
JOHNSON & JOHNSON19.17%368 832
NOVARTIS12.82%222 846
ROCHE HOLDING LTD.6.15%216 979
PFIZER9.08%211 188
MERCK AND COMPANY-7.64%148 286